Medium materiality6/10
Zymeworks price target raised to $32 from $31 at Truist
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst Truist Financial raises ZYME target to $32 from $31; current price $23.77. Upside implied by the higher target.
- Target: $32 (up from $31); price: $23.77; Firm: Truist Financial
Key facts
- 01
Target: $32
- 02
Posted price: $23.77
- 03
Analyst firm: Truist Financial
- 04
Analyst: Gregory Renza
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.